Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs PRIMO Health Partners

Two GLP-1 desks, one scoreboard. We put MadeMed and PRIMO Health Partners head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 488 · Grade C

PRIMO Health Partners

Visit PRIMO Health Partners Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 46 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make PRIMO Health Partners a bad call — it's best for patients wanting a simple physician-led glp-1 consult with local pharmacy pickup. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
40
Supply Reliability
84
63
Transparency
94
27
Access Breadth
76
30
Clinical Oversight
84
63
Track Record
82
60
MadeMedBrief Score 86 · 46PRIMO Health Partners

Price, coverage & the tracker

MadeMedPRIMO Health Partners
Brief Score86/100 (B)46/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)Not disclosed
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)Not disclosed
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

PRIMO Health Partners: New to the tracker on 1 August 2026. This program publishes no monthly medication price, so there is no line for us to track until it does.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.